Traws Pharma

TRAW

市值 US$568萬

NEWTOWN, Pa., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today reported financial results and provided recent business highlights for the quarter ended June 30, 2026, including updates on its lead clinical programs and April 2026 financing.

Resubmission of updated data package to MHRA, expected in 3Q 2026, to enable Phase 2a human influenza Challenge study to proceed Resubmission of updated data package to MHRA, expected in 3Q 2026, to enable Phase 2a human influenza Challenge study to proceed

Traws Pharma Inc. (NASDAQ:TRAW) shares are trading lower on Monday as the company faces regulatory challenges regarding its influenza treatment program.

U.S. stock futures were higher this morning, with the Dow futures gaining more than 400 points on Monday.

NEWTOWN, Pa., June 12, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats, today announced that the planned test of tivoxavir marboxil (TXM) in a Phase 2a human influenza challenge study has been deferred due to a negative review of the program by the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA).

Broad-spectrum antiviral agent with potential utility against Hantavirus, Ebola and Lassa Utilizing a novel dual-strike mechanism, the proprietary combination agent has the potential to deliver a low pill burden option to manage existing and future outbreaks Interactions planned with the US Centers for Disease Control and Prevention (CDC), and ongoing with the Nigerian National Agency for Food and Drug Administration and Control (NAFDAC), and the African Medicines Agency (AMA) to fast-track clinical development, emergency manufacturing scale-up, and global access NEWTOWN, Pa., May 27, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats, today announced the advancement of a novel proprietary broad-spectrum combination anti-viral agent in its portfolio.

Private financing of up to $60M offering of common stock (with $10M upfront) and milestone-based warrants expected to support operations into Q1 2027

It's been a struggle to secure funding for hantavirus research because these viruses haven't been a priority.

Traws Pharma, Inc. (NASDAQ:TRAW) shares are up during Friday's session, trading higher by 25.86% as the company is advancing potential clinical candidates for the treatment of hantavirus infections.

NEWTOWN, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced plans to advance potential clinical candidates for the treatment of hantavirus infections.